Integrated Biopharma Reports Q2 2025 Results

TL;DR

IBP Q2 2025: Assets $30.3M, Liab $30.1M, Net Loss $0.01/share.

AI Summary

Integrated Biopharma Inc. filed its 10-Q for the period ending December 31, 2024. The company reported total assets of $30.34 million and total liabilities of $30.13 million for the six months ended December 31, 2024. This resulted in a net loss of $0.01 per share for the three months ended December 31, 2024.

Why It Matters

This filing provides a snapshot of Integrated Biopharma's financial health and operational performance for the second quarter of fiscal year 2025, crucial for investors assessing its current standing.

Risk Assessment

Risk Level: medium — The company shows a very narrow margin between assets and liabilities, and a net loss per share, indicating potential financial strain.

Key Numbers

• $30.34M — Total Assets (As of December 31, 2024)
• $30.13M — Total Liabilities (As of December 31, 2024)
• $0.01 — Net Loss Per Share (For the three months ended December 31, 2024)

Key Players & Entities

• INTEGRATED BIOPHARMA INC (company) — Filer
• 2024-12-31 (date) — Reporting Period End Date
• $30,335,620 (dollar_amount) — Total Assets as of December 31, 2024
• $30,134,510 (dollar_amount) — Total Liabilities as of December 31, 2024
• $0.01 (dollar_amount) — Net Loss Per Share for the three months ended December 31, 2024

FAQ

Key Financial Figures

• $0.002 — were 30,300,720 shares of common stock, $0.002 par value per share, of the registrant

Filing Documents

• inbp20241231_10q.htm (10-Q) — 1047KB
• ex_771540.htm (EX-31.1) — 13KB
• ex_771541.htm (EX-31.2) — 15KB
• ex_771542.htm (EX-32.1) — 9KB
• ex_771543.htm (EX-32.2) — 7KB
• 0001437749-25-003744.txt ( ) — 5234KB
• inbp-20241231.xsd (EX-101.SCH) — 42KB
• inbp-20241231_cal.xml (EX-101.CAL) — 32KB
• inbp-20241231_def.xml (EX-101.DEF) — 286KB
• inbp-20241231_lab.xml (EX-101.LAB) — 247KB
• inbp-20241231_pre.xml (EX-101.PRE) — 309KB
• inbp20241231_10q_htm.xml (XML) — 939KB

Financial Information

Part I. Financial Information Item 1. Condensed Consolidated Statements of Operations for the Three and Six Months Ended December 31, 2024 and 2023 (unaudited) 2 Condensed Consolidated Balance Sheets as of December 31, 2024 and June 30, 2024 (unaudited) 3 Condensed Consolidated Statement of Stockholders' Equity for the Three and Six Months Ended December 31, 2024 and 2023 (unaudited) 4 Condensed Consolidated Statements of Cash Flows for the Six Months Ended December 31, 2024 and 2023 (unaudited) 5 Notes to Condensed Consolidated Financial Statements (unaudited) 6 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 17 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 24 Item 4.

Controls and Procedures

Controls and Procedures 24

Other Information

Part II. Other Information Item 1.

Legal Proceedings

Legal Proceedings 24 Item 1A.

Risk Factors

Risk Factors 24 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 25 Item 3. Defaults Upon Senior Securities 25 Item 4. Mine Safety Disclosure 25 Item 5. Other Information 25 Item 6. Exhibits 25 Other

Signatures

Signatures 26 Cautionary Statement Regarding Forward-Looking Statements Certain statements in this Quarterly Report on Form 10-Q may constitute "forward-looking" statements as defined in Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), the Private Securities Litigation Reform Act of 1995 (the "PSLRA") or in releases made by the Securities and Exchange Commission ("SEC"), all as may be amended from time to time. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of Integrated BioPharma, Inc. and its subsidiaries (collectively, the "Company") or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, changes in general economic and business conditions; loss of market share through competition; introduction of competing products by other companies; the timing of regulatory approval and the introduction of new products by the Company; changes in industry capacity; pressure on prices from competition or from purchasers of the Company's products; regulatory changes in the pharmaceutical manufacturing industry and nutraceutical industry; regulatory obstacles to the introduction of new technologies or products that are important to the Company; availability of qualified personnel; the loss of any significant customers or suppliers; inflation (including those caused by tariffs) and tightened labor markets; the impact of the war in Ukraine; the impact of the Israel-Hamas war, and other factors both referenced and not referenced in the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2024 ("Form 10-K"), as filed with the SEC. Statements that are not historical fact are forward-looking statemen

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS INTEGRATED BIOPHARMA, INC. AND ITS SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share amounts) (Unaudited) Three months ended Six months ended December 31, December 31, 2024 2023 2024 2023 Sales, net $ 12,614 $ 11,509 $ 26,231 $ 24,424 Cost of sales 11,443 10,989 23,689 23,072 Gross profit 1,171 520 2,542 1,352 Selling and administrative expenses 969 972 1,850 1,858 Operating income (loss) 202 ( 452 ) 692 ( 506 ) Other income (expense), net Interest income, net 11 2 25 10 Other income, net ( 28 ) ( 2 ) ( 28 ) ( 2 ) Other income (expense), net ( 17 ) - ( 3 ) 8 Income (loss) before income taxes 185 ( 452 ) 689 ( 498 ) Income tax expense (benefit), net 69 ( 70 ) 314 ( 57 ) Net income (loss) $ 116 $ ( 382 ) $ 375 $ ( 441 ) Basic net income (loss) per common share $ 0.00 $ (0.01 ) $ 0.01 $ (0.02 ) Diluted net income (loss) per common share $ 0.00 $ (0.01 ) $ 0.01 $ (0.02) Weighted average common shares outstanding - basic 30,174,664 30,099,610 30,137,137 30,032,762 Add: Equivalent shares outstanding - Stock Options 1,128,347 - 673,264 - Weighted average common shares outstanding - diluted 31,303,011 30,099,610 30,810,401 30,032,762 See accompanying notes to unaudited condensed consolidated financial statements. 2 INTEGRATED BIOPHARMA, INC. AND ITS SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL CONDITION (in thousands, except share and per share amounts) (Unaudited) December 31, June 30, 2024 2024 Assets Current Assets: Cash $ 2,461 $ 1,677 Accounts receivable, net 4,228 4,668 Inventories 11,066 11,244 Other current assets 398 286 Total current assets 18,153 17,875 Property and equipment, net 1,771 1,885 Operating lease right-of-use assets (includ

View Full Filing

View this 10-Q filing on SEC EDGAR